Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
ALBUQUERQUE, N.M., December 03, 2008 /PRNewswire/ -- The nation's first scientific study on the relationship between smoking and respiratory disease among Hispanic versus non-Hispanic white (NHW) women revealed that NHW women smokers were at greater...
HASBROUCK HEIGHTS, N.J.,Dec. 3, 2008--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today positive new data from a recently completed clinical trial of NX-1207, the Company’s investigational drug for BPH. The trial data shows that...
DALLAS--(BUSINESS WIRE)--Dec 3, 2008 - Memgen today announced that two of its clinical trials were selected for poster presentations at the annual meeting of the American Society of Hematology (ASH) on December 6-9.
Both presentations highlight...
CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel...
BETHESDA, Md., December 03, 2008 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 3, 2008 - Sepracor Inc. (Nasdaq: SEPR) today announced that clinical study data for eslicarbazepine acetate in the treatment of epilepsy will be presented at the 62nd annual meeting of the American Epilepsy...
SOUTH SAN FRANCISCO, Calif., December 03, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at...
SOUTH SAN FRANCISCO, Calif., December 03, 2008 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...
Clinical Results Demonstrate Novel Mechanism Increases Bone Mineral Density and Increases Levels of Hemoglobin and Hematocrit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 3, 2008 - Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a...
NEW YORK--(BUSINESS WIRE)--Dec 3, 2008 - Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of experiencing a...
Results suggest that the Company's Metformin chewing gum is therapeutically equivalent to traditional Metformin tablets
WORCESTER, MA, December 2, 2008 (GlobeNewswire) - Generex Biotechnology Corporation (NasdaqCM:GNBT) (www.generex.com...
PN 400 Demonstrated Statistically Significant Fewer Gastric Ulcers vs. Enteric Coated Naproxen
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec 3, 2008 - POZEN Inc. (NASDAQ: POZN), today announced positive Phase 3 trial results for its PN 400 product...
LONDON, Dec. 3, 2008-AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric-coated naproxen 500 mg and...
First-line trial currently shows median overall survival of 27.5 months
for OGX-011 in combination with docetaxel and prednisone and a 16.9
months overall survival for docetaxel and prednisone alone.
Achievement of...
DUBLIN, Calif., December 02, 2008 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th...
Efficacy data collected on healthy volunteers (GFT505-1084 studies) demonstrate clear beneficial effects of GFT505 on plasma lipids and inflammation markers.
The anticipated large efficacy/safety ratio accelerates...
MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Dec 2, 2008 - Gemin X Pharmaceuticals announced today that preclinical data from the company's targeted cancer therapy, obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor, will be presented in three...
EDISON, N.J., December 02, 2008 /PRNewswire/ -- Daiichi Sankyo, Inc. , today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American Society of...
LA JOLLA, Calif., December 02, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with...
Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain
SKOKIE, Ill., December 02, 2008 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...
More...
